ClinicalTrials.gg

Program

THDB0206

A development code. Also written as “THDB0206 Injection”, “THDB0206 injection-Upper arm” and “THDB0206 Injection-Abdomen”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Tonghua Dongbao Pharmaceutical.

Furthest: phase 3, since Apr 17, 20234 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tonghua Dongbao Pharmaceutical40 open or runningphase 3since Apr 17, 2023Apr 17, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2023First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT05834868 · 1,040 enrolled · China
  2. Nov 17, 2023Phase 1 study in HealthyNCT06153329 · 39 enrolled · China
  3. Nov 14, 2025Phase 1 study in Healthy ParticipantsNCT07257627 · 27 enrolled · China
  4. Dec 2, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT07282054 · 550 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07282054Diabetes Mellitus, Type 1 · China3CompletedJan 23, 2025550
NCT07257627Healthy Participants · China1CompletedDec 2, 202427
NCT06153329Healthy · China1CompletedJun 6, 202239
NCT05834868Diabetes Mellitus, Type 2 · China3CompletedDec 10, 20241,040

How it is read

Names in the registry

  • “THDB0206 Injection”, 1 entry
  • “THDB0206”, 1 entry
  • “THDB0206 injection-Upper arm”, 1 entry
  • “THDB0206 Injection-Abdomen”, 1 entry
  • “THDB0206 Injection-Thigh”, 1 entry

Codes read as this program: THDB0206.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.